A First-in-Human Study of CEE321 in Adult Subjects
NCT04612062
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
CEE321
Sponsor
Novartis Pharmaceuticals